83 related articles for article (PubMed ID: 17346540)
1. Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model.
Milam MR; Celestino J; Wu W; Broaddus RR; Schmeler KM; Slomovitz BM; Soliman PT; Gershenson DM; Wang H; Ellenson LH; Lu KH
Am J Obstet Gynecol; 2007 Mar; 196(3):247.e1-5. PubMed ID: 17346540
[TBL] [Abstract][Full Text] [Related]
2. Overactive mTOR signaling leads to endometrial hyperplasia in aged women and mice.
Bajwa P; Nielsen S; Lombard JM; Rassam L; Nahar P; Rueda BR; Wilkinson JE; Miller RA; Tanwar PS
Oncotarget; 2017 Jan; 8(5):7265-7275. PubMed ID: 27980219
[TBL] [Abstract][Full Text] [Related]
3. Loss of phosphatase and tensin homologue deleted on chromosome 10 and phosphorylation of mammalian target of rapamycin are associated with progesterone refractory endometrial hyperplasia.
Milam MR; Soliman PT; Chung LH; Schmeler KM; Bassett RL; Broaddus RR; Lu KH
Int J Gynecol Cancer; 2008; 18(1):146-51. PubMed ID: 17466036
[TBL] [Abstract][Full Text] [Related]
4. Primary chemoprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone in the PTEN heterozygote murine model.
Wu W; Celestino J; Milam MR; Schmeler KM; Broaddus RR; Ellenson LH; Lu KH
Int J Gynecol Cancer; 2008; 18(2):329-38. PubMed ID: 18334011
[TBL] [Abstract][Full Text] [Related]
5. PTEN sequence analysis in endometrial hyperplasia and endometrial carcinoma in Slovak women.
Gbelcová H; Bakeš P; Priščáková P; Šišovský V; Hojsíková I; Straka Ľ; Konečný M; Markus J; D'Acunto CW; Ruml T; Böhmer D; Danihel Ľ; Repiská V
Anal Cell Pathol (Amst); 2015; 2015():746856. PubMed ID: 26114084
[TBL] [Abstract][Full Text] [Related]
6. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
Panwalkar A; Verstovsek S; Giles FJ
Cancer; 2004 Feb; 100(4):657-66. PubMed ID: 14770419
[TBL] [Abstract][Full Text] [Related]
7. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
[TBL] [Abstract][Full Text] [Related]
8. An inducible knockout mouse to model the cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias.
Mirantes C; Eritja N; Dosil MA; Santacana M; Pallares J; Gatius S; Bergadà L; Maiques O; Matias-Guiu X; Dolcet X
Dis Model Mech; 2013 May; 6(3):710-20. PubMed ID: 23471917
[TBL] [Abstract][Full Text] [Related]
9. RAD001 (Everolimus) Can prevent tamoxifen-related endometrial and stromal hyperplasia.
Erdemoglu E; Güney M; Take G; Giray SG; Mungan T
Int J Gynecol Cancer; 2009 Apr; 19(3):375-9. PubMed ID: 19407562
[TBL] [Abstract][Full Text] [Related]
10. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
Neshat MS; Mellinghoff IK; Tran C; Stiles B; Thomas G; Petersen R; Frost P; Gibbons JJ; Wu H; Sawyers CL
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10314-9. PubMed ID: 11504908
[TBL] [Abstract][Full Text] [Related]
11. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo.
Kwon CH; Zhu X; Zhang J; Baker SJ
Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12923-8. PubMed ID: 14534328
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells.
Cao C; Subhawong T; Albert JM; Kim KW; Geng L; Sekhar KR; Gi YJ; Lu B
Cancer Res; 2006 Oct; 66(20):10040-7. PubMed ID: 17047067
[TBL] [Abstract][Full Text] [Related]
13. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis.
Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F
Eur J Obstet Gynecol Reprod Biol; 2018 Dec; 231():104-110. PubMed ID: 30342311
[TBL] [Abstract][Full Text] [Related]
14. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
Shi Y; Gera J; Hu L; Hsu JH; Bookstein R; Li W; Lichtenstein A
Cancer Res; 2002 Sep; 62(17):5027-34. PubMed ID: 12208757
[TBL] [Abstract][Full Text] [Related]
15. PTEN mutations as predictive marker for the high-grade endometrial cancer development in slovak women.
Gbelcová H; Gergely L; Šišovský V; Straka Ľ; Böhmer D; Pastoráková A; Sušienková K; Repiská V; Korbeľ M; Danihel Ľ; Priščáková P
Physiol Res; 2022 Dec; 71(Suppl 1):S125-S135. PubMed ID: 36592448
[TBL] [Abstract][Full Text] [Related]
16. Effect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status.
Fong P; Meng LR
Med Sci Monit Basic Res; 2014 Sep; 20():146-52. PubMed ID: 25266877
[TBL] [Abstract][Full Text] [Related]
17. Association of mismatch repair deficiency with PTEN frameshift mutations in endometrial cancers and the precursors in a Japanese population.
Kanaya T; Kyo S; Sakaguchi J; Maida Y; Nakamura M; Takakura M; Hashimoto M; Mizumoto Y; Inoue M
Am J Clin Pathol; 2005 Jul; 124(1):89-96. PubMed ID: 15923161
[TBL] [Abstract][Full Text] [Related]
18. PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2.
Levitt RJ; Georgescu MM; Pollak M
Biochem Biophys Res Commun; 2005 Nov; 336(4):1056-61. PubMed ID: 16154532
[TBL] [Abstract][Full Text] [Related]
19. Lean Body Weight and Metformin Are Insufficient to Prevent Endometrial Hyperplasia in Mice Harboring Inactivating Mutations in PTEN.
Iglesias DA; Zhang Q; Celestino J; Sun CC; Yates MS; Schmandt RE; Lu KH
Oncology; 2017; 92(2):109-114. PubMed ID: 27931017
[TBL] [Abstract][Full Text] [Related]
20. DNA mismatch repair deficiency accelerates endometrial tumorigenesis in Pten heterozygous mice.
Wang H; Douglas W; Lia M; Edelmann W; Kucherlapati R; Podsypanina K; Parsons R; Ellenson LH
Am J Pathol; 2002 Apr; 160(4):1481-6. PubMed ID: 11943731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
